Clinical Decision-making With New Biologics for Severe Asthma

Faculty

Nicola A. Hanania, MD, MS
Associate Professor of Medicine Director, Airways Clinical Research
Associate Professor of Medicine
Baylor College of Medicine
Houston, Texas

Flavia Hoyte, MD
Associate Professor of Medicine, Division of Allergy and Immunology
Director, Allergy and Clinical Immunology Fellowship Program
National Jewish Health/University of Colorado
Denver, Colorado

Program Description

As the treatment armamentarium for severe asthma continues to expand, best practices within its management will continue to evolve, guided by the integration of the latest scientific information, evidence-based recommendations, and an accumulated of real-world clinical experience. This POC¹⁰¹ Microlearning Series™ will be led by two expert faculty who will deliver focused education on the latest developments in biologic therapies for severe asthma that target upstream inflammatory mediators of disease. Utilizing a multimedia format that combines text and video, faculty will discuss the placement of new targeted biologic therapies, treatment selection informed by unique patient and disease profiles, and finally, strategies for monitoring effectiveness and switching.

Target Audience

The educational design of this activity addresses the needs of pulmonologists, clinical immunologists, and other physicians involved in the management of patients with severe asthma.

Learning Objectives

After completing this activity, participants will be better prepared to:

• Tailor therapeutic regimens for patients with severe asthma using newer biologic treatments to reduce symptoms, prevent exacerbations, decrease systemic corticosteroid use, and reflect shared clinical decision making

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour(s) (which includes 0.1 hour(s) of pharmacology).

Disclosure of Conflicts of Interest

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the ACCME and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Nicola A. Hanania, MD - Consultant: Amgen Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Genentech, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc. sanofi-aventis U.S. LLC, Teva Pharmaceutical Industries Ltd.; Contracted Research: AstraZeneca plc, Boehringer Ingelheim GmbH, Novartis Pharmaceuticals Corporation, Genentech, Inc., GlaxoSmithKline, sanofi-aventis U.S. LLC, Teva Pharmaceutical Industries Ltd.; Speakers Bureau: Regeneron Pharmaceuticals, Inc.

Flavia Hoyte, MD -  Consultant: AstraZeneca plc; Contracted Research: Genentech, Inc., sanofi-aventis U.S. LLC, Teva Pharmaceutical Industries Ltd.; Honoraria: GlaxoSmithKline; Speakers Bureau: AstraZeneca plc; Stock Shareholder: Amgen, Johnson & Johnson, Merck

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP: Nothing to disclose
Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

In order to received credit, participants must complete the following:

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Preactivity Questions.
3. Review the activity content.
4. Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation.

Term of Offering

This activity was released on March 29, 2022, and is valid for one year. Requests for credit must be made no later than March 29, 2023. 

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Global Education Group Contact Information

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.